Effectiveness of Benralizumab in Severe Eosinophilic Asthma
Benralizumab is an interluken-5 receptor monoclonal antibody licensed for the treatment of severe eosinophilic asthma....
20 September, 2020
Benralizumab is an interluken-5 receptor monoclonal antibody licensed for the treatment of severe eosinophilic asthma....